Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis.

Florez H, Hernández-Rodríguez J, Muxi A, Carrasco JL, Prieto-González S, Cid MC, Espinosa G, Gómez-Puerta JA, Monegal A, Guañabens N, Peris P.

Rheumatology (Oxford). 2019 Oct 19. pii: kez464. doi: 10.1093/rheumatology/kez464. [Epub ahead of print]

PMID:
31628810
2.

Rheumatoid Arthritis Initiating as Palindromic Rheumatism: A Distinct Clinical Phenotype?

Castellanos-Moreira R, Rodriguez-Garcia SC, Gómez-Puerta JA, Ruiz-Esquide V, Camacho O, Ramírez J, Cuervo A, Morlá R, Cañete JD, Haro I, Sanmarti R.

J Rheumatol. 2019 Aug 1. pii: jrheum.190061. doi: 10.3899/jrheum.190061. [Epub ahead of print]

PMID:
31371648
3.

Clinical characteristics and renal prognosis associated with interstitial fibrosis and tubular atrophy (IFTA) and vascular injury in lupus nephritis biopsies.

Leatherwood C, Speyer CB, Feldman CH, D'Silva K, Gómez-Puerta JA, Hoover PJ, Waikar SS, McMahon GM, Rennke HG, Costenbader KH.

Semin Arthritis Rheum. 2019 Dec;49(3):396-404. doi: 10.1016/j.semarthrit.2019.06.002. Epub 2019 Jun 11.

PMID:
31277928
4.

Overrepresentation of Elderly Subjects in a Population-Based Study of Antiphospholipid Syndrome: Comment on the Article by Duarte-García et al.

Gómez-Puerta JA, Cervera R, Alarcón GS.

Arthritis Rheumatol. 2019 Oct;71(10):1768-1769. doi: 10.1002/art.41002. Epub 2019 Sep 2. No abstract available.

PMID:
31131989
5.

Antinuclear antibodies mitotic patterns and their clinical associations.

Betancur JF, Gómez-Puerta JA.

Ann Rheum Dis. 2019 Apr 29. pii: annrheumdis-2019-215428. doi: 10.1136/annrheumdis-2019-215428. [Epub ahead of print] No abstract available.

PMID:
31036628
6.

Predictors of Remission and Low Disease Activity State in Systemic Lupus Erythematosus: Data from a Multiethnic, Multinational Latin American Cohort.

Ugarte-Gil MF, Wojdyla D, Pons-Estel GJ, Quintana R, Gómez-Puerta JA, Catoggio LJ, Alvarellos A, Saurit V, Borba E, Sato E, Costallat L, Da Silva NA, Iglesias-Gamarra A, Neira O, Reyes-Llerena G, Cardiel MH, Amigo MC, Acevedo-Vásquez E, Esteva-Spinetti MH, Alarcón GS, Pons-Estel BA.

J Rheumatol. 2019 Oct;46(10):1299-1308. doi: 10.3899/jrheum.180433. Epub 2019 Mar 1.

PMID:
30824636
7.

HMGB1+ microparticles present in urine are hallmarks of nephritis in patients with systemic lupus erythematosus.

Burbano C, Gómez-Puerta JA, Muñoz-Vahos C, Vanegas-García A, Rojas M, Vásquez G, Castaño D.

Eur J Immunol. 2019 Feb;49(2):323-335. doi: 10.1002/eji.201847747. Epub 2019 Jan 7.

PMID:
30537116
8.

Uncommon patterns of antinuclear antibodies recognizing mitotic spindle apparatus antigens and clinical associations.

Betancur JF, Londoño A, Estrada VE, Puerta SL, Osorno SM, Loaiza A, Carmona JA, Gómez-Puerta JA.

Medicine (Baltimore). 2018 Aug;97(34):e11727. doi: 10.1097/MD.0000000000011727.

9.

First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR).

Pons-Estel BA, Bonfa E, Soriano ER, Cardiel MH, Izcovich A, Popoff F, Criniti JM, Vásquez G, Massardo L, Duarte M, Barile-Fabris LA, García MA, Amigo MC, Espada G, Catoggio LJ, Sato EI, Levy RA, Acevedo Vásquez EM, Chacón-Díaz R, Galarza-Maldonado CM, Iglesias Gamarra AJ, Molina JF, Neira O, Silva CA, Vargas Peña A, Gómez-Puerta JA, Scolnik M, Pons-Estel GJ, Ugolini-Lopes MR, Savio V, Drenkard C, Alvarellos AJ, Ugarte-Gil MF, Babini A, Cavalcanti A, Cardoso Linhares FA, Haye Salinas MJ, Fuentes-Silva YJ, Montandon de Oliveira E Silva AC, Eraso Garnica RM, Herrera Uribe S, Gómez-Martín D, Robaina Sevrini R, Quintana RM, Gordon S, Fragoso-Loyo H, Rosario V, Saurit V, Appenzeller S, Dos Reis Neto ET, Cieza J, González Naranjo LA, González Bello YC, Collado MV, Sarano J, Retamozo S, Sattler ME, Gamboa-Cárdenas RV, Cairoli E, Conti SM, Amezcua-Guerra LM, Silveira LH, Borba EF, Pera MA, Alba Moreyra PB, Arturi V, Berbotto GA, Gerling C, Gobbi CA, Gervasoni VL, Scherbarth HR, Brenol JCT, Cavalcanti F, Costallat LTL, Da Silva NA, Monticielo OA, Seguro LPC, Xavier RM, Llanos C, Montúfar Guardado RA, Garcia de la Torre I, Pineda C, Portela Hernández M, Danza A, Guibert-Toledano M, Reyes GL, Acosta Colman MI, Aquino AM, Mora-Trujillo CS, Muñoz-Louis R, García Valladares I, Orozco MC, Burgos PI, Betancur GV, Alarcón GS; Grupo Latino Americano de Estudio del Lupus (GLADEL) and Pan-American League of Associations of Rheumatology (PANLAR).

Ann Rheum Dis. 2018 Nov;77(11):1549-1557. doi: 10.1136/annrheumdis-2018-213512. Epub 2018 Jul 25.

10.

Utility of urinary transferrin and ceruloplasmin in patients with systemic lupus erythematosus for differentiating patients with lupus nephritis.

Urrego T, Ortiz-Reyes B, Vanegas-García AL, Muñoz CH, González LA, Vásquez G, Gómez-Puerta JA.

Reumatol Clin. 2020 Jan - Feb;16(1):17-23. doi: 10.1016/j.reuma.2018.02.002. Epub 2018 Mar 9. English, Spanish.

11.

Anti C1q antibodies. A promising biomarker for cocaine-levamisole induced vasculitis.

Gómez-Puerta JA, Muñoz CH, Vanegas-García AL, Urrego T, Vásquez G, González LA.

Reumatol Clin. 2019 Sep - Oct;15(5):e66-e67. doi: 10.1016/j.reuma.2017.11.002. Epub 2017 Dec 15. English, Spanish. No abstract available.

12.

Urinary neutrophil gelatinase-associated lipocalin and monocyte chemoattractant protein 1 as biomarkers for lupus nephritis in Colombian SLE patients.

Gómez-Puerta JA, Ortiz-Reyes B, Urrego T, Vanegas-García AL, Muñoz CH, González LA, Cervera R, Vásquez G.

Lupus. 2018 Apr;27(4):637-646. doi: 10.1177/0961203317738226. Epub 2017 Oct 26.

PMID:
29073812
13.

Race/Ethnicity and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus.

Barbhaiya M, Feldman CH, Guan H, Gómez-Puerta JA, Fischer MA, Solomon DH, Everett B, Costenbader KH.

Arthritis Rheumatol. 2017 Sep;69(9):1823-1831. doi: 10.1002/art.40174. Epub 2017 Aug 13.

14.

Infiltrating CD16+ Are Associated with a Reduction in Peripheral CD14+CD16++ Monocytes and Severe Forms of Lupus Nephritis.

Barrera García A, Gómez-Puerta JA, Arias LF, Burbano C, Restrepo M, Vanegas AL, Muñoz CH, Rojas M, González LA, Vásquez G.

Autoimmune Dis. 2016;2016:9324315. doi: 10.1155/2016/9324315. Epub 2016 Dec 13.

15.

Role of TWEAK/Fn14 signalling pathway in lupus nephritis and other clinical settings.

González-Sánchez DA, Álvarez CM, Vásquez G, Gómez-Puerta JA.

Nefrologia. 2017 Mar - Apr;37(2):118-125. doi: 10.1016/j.nefro.2016.05.020. Epub 2016 Aug 29. Review. English, Spanish.

16.

Antiphospholipid Antibodies: From General Concepts to Its Relation with Malignancies.

Gómez-Puerta JA, Espinosa G, Cervera R.

Antibodies (Basel). 2016 Aug 2;5(3). pii: E18. doi: 10.3390/antib5030018. Review.

17.

[Relationship between Obesity, Adipokines and Systemic Lupus Erythematosus].

Urrego T, Vásquez GM, Gómez-Puerta JA.

Rev Fac Cien Med Univ Nac Cordoba. 2016;73(1):32-9. Review. Spanish.

PMID:
27419894
18.

IgG4-related disease: A concise review of the current literature.

Ardila-Suarez O, Abril A, Gómez-Puerta JA.

Reumatol Clin. 2017 May - Jun;13(3):160-166. doi: 10.1016/j.reuma.2016.05.009. Epub 2016 Jun 18. Review. English, Spanish.

19.

[Diagnosis of antiphospholipid syndrome: From an historical perspective to the emergence of new autoantibodies].

Ardila-Suarez O, Gómez-Puerta JA, Khamashta MA.

Med Clin (Barc). 2016 Jun 17;146(12):555-60. doi: 10.1016/j.medcli.2016.01.005. Epub 2016 Mar 5. Spanish. No abstract available.

PMID:
26961394
20.

Organ Damage and Quality of Life in Antiphospholipid Syndrome.

Alba P, Gómez-Puerta JA, Goycochea-Robles MV, Amigo MC.

Curr Rheumatol Rep. 2016 Feb;18(2):7. doi: 10.1007/s11926-015-0556-6. Review.

PMID:
26769306
21.

Diagnostic and therapeutic delay of rheumatoid arthritis and its relationship with health care devices in Catalonia. The AUDIT study.

Corominas H, Narváez J, Díaz-Torné C, Salvador G, Gomez-Caballero ME, de la Fuente D, Campoy E, Roig-Vilaseca D, Clavaguera T, Morlà R, Torrente-Segarra V, Arasa X, Gomez-Puerta JA, Möller I, Alegre C, Graell E, Ponce A, Lisbona MP, Pérez-Garcia C, Fíguls R, Sirvent E, Poca V, Sanmartí R.

Reumatol Clin. 2016 May-Jun;12(3):146-50. doi: 10.1016/j.reuma.2015.08.002. Epub 2015 Sep 8. English, Spanish.

22.

Racial and Ethnic Differences in Mortality and Cardiovascular Events Among Patients With End-Stage Renal Disease Due to Lupus Nephritis.

Gómez-Puerta JA, Feldman CH, Alarcón GS, Guan H, Winkelmayer WC, Costenbader KH.

Arthritis Care Res (Hoboken). 2015 Oct;67(10):1453-62. doi: 10.1002/acr.22562.

23.

Racial/Ethnic variation in all-cause mortality among United States medicaid recipients with systemic lupus erythematosus: a Hispanic and asian paradox.

Gómez-Puerta JA, Barbhaiya M, Guan H, Feldman CH, Alarcón GS, Costenbader KH.

Arthritis Rheumatol. 2015 Mar;67(3):752-60. doi: 10.1002/art.38981.

24.

Prolonged remission in SLE revisited: an old wine in a new bottle.

Gómez-Puerta JA, Pons-Estel BA, Cervera R.

J Rheumatol. 2014 Sep;41(9):1728-31. doi: 10.3899/jrheum.140668. No abstract available.

PMID:
25226594
25.

Is there subclinical synovitis in patients with palindromic rheumatism in the intercritical period? a clinical and ultrasonographic study according to anticitrullinated protein antibody status.

Cabrera-Villalba S, Ramirez J, Salvador G, Ruiz-Esquide V, Hernández MV, Inciarte-Mundo J, Gómez-Puerta JA, Cañete JD, Sanmarti R.

J Rheumatol. 2014 Aug;41(8):1650-5. doi: 10.3899/jrheum.131545. Epub 2014 Jul 15.

PMID:
25028368
26.

Erythropoiesis-stimulating Agent Use among Patients with Lupus Nephritis Approaching End-stage Renal Disease.

Gómez-Puerta JA, Waikar SS, Solomon DH, Liu J, Alarcón GS, Winkelmayer WC, Costenbader KH.

J Clin Cell Immunol. 2013 Dec 1;4(6):179.

27.

Differences in synovial fluid cytokine levels but not in synovial tissue cell infiltrate between anti-citrullinated peptide/protein antibody-positive and -negative rheumatoid arthritis patients.

Gómez-Puerta JA, Celis R, Hernández MV, Ruiz-Esquide V, Ramírez J, Haro I, Cañete JD, Sanmartí R.

Arthritis Res Ther. 2013 Nov 7;15(6):R182. doi: 10.1186/ar4372.

28.

Diagnosis and classification of the antiphospholipid syndrome.

Gómez-Puerta JA, Cervera R.

J Autoimmun. 2014 Feb-Mar;48-49:20-5. doi: 10.1016/j.jaut.2014.01.006. Epub 2014 Jan 24. Review.

PMID:
24461539
29.

High prevalence of prothrombotic abnormalities in multifocal osteonecrosis: description of a series and review of the literature.

Gómez-Puerta JA, Peris P, Reverter JC, Espinosa G, Martinez-Ferrer A, Monegal A, Monteagudo J, Tàssies D, Guañabens N.

Medicine (Baltimore). 2013 Nov;92(6):295-304. doi: 10.1097/MD.0000000000000007. Review.

30.

Laryngeal assessment by videolaryngostroboscopy in patients with rheumatoid arthritis.

Gómez-Puerta JA, Cisternas A, Hernández MV, Ruiz-Esquide V, Vilaseca I, Sanmartí R.

Reumatol Clin. 2014 Jan-Feb;10(1):32-6. doi: 10.1016/j.reuma.2013.04.006. Epub 2013 Jul 3. English, Spanish.

31.

The association between silica exposure and development of ANCA-associated vasculitis: systematic review and meta-analysis.

Gómez-Puerta JA, Gedmintas L, Costenbader KH.

Autoimmun Rev. 2013 Oct;12(12):1129-35. doi: 10.1016/j.autrev.2013.06.016. Epub 2013 Jun 29. Review.

32.

Catastrophic antiphospholipid syndrome: diagnosis and management in pregnancy.

Gómez-Puerta JA, Espinosa G, Cervera R.

Clin Lab Med. 2013 Jun;33(2):391-400. doi: 10.1016/j.cll.2013.01.003. Epub 2013 Apr 19. Review.

PMID:
23702126
33.

Are there additional options for the treatment of refractory obstetric antiphospholipid syndrome?

Gómez-Puerta JA, Cervera R.

Lupus. 2013 Jun;22(7):754-5. doi: 10.1177/0961203313490433. Epub 2013 May 17. No abstract available.

PMID:
23687066
34.

Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.

Gomez-Puerta JA, Mócsai A.

Curr Top Med Chem. 2013;13(6):760-73. Review.

35.

Toxoplasma gondii: bystander or cofactor in rheumatoid arthritis.

Fischer S, Agmon-Levin N, Shapira Y, Porat Katz BS, Graell E, Cervera R, Stojanovich L, Gómez Puerta JA, Sanmartí R, Shoenfeld Y.

Immunol Res. 2013 Jul;56(2-3):287-92. doi: 10.1007/s12026-013-8402-2.

PMID:
23553228
36.

Association of discoid lupus erythematosus with other clinical manifestations among patients with systemic lupus erythematosus.

Merola JF, Prystowsky SD, Iversen C, Gomez-Puerta JA, Norton T, Tsao P, Massarotti E, Schur P, Bermas B, Costenbader KH.

J Am Acad Dermatol. 2013 Jul;69(1):19-24. doi: 10.1016/j.jaad.2013.02.010. Epub 2013 Mar 28.

37.

Palindromic rheumatism with positive anticitrullinated peptide/protein antibodies is not synonymous with rheumatoid arthritis. A longterm followup study.

Sanmartí R, Cabrera-Villalba S, Gómez-Puerta JA, Ruiz-Esquide V, Hernández MV, Salvador G, Ramirez J, Viñas O, Cañete JD.

J Rheumatol. 2012 Oct;39(10):1929-33. doi: 10.3899/jrheum.120568. Epub 2012 Aug 1.

PMID:
22859345
38.

Relapsing catastrophic antiphospholipid syndrome potential role of microangiopathic hemolytic anemia in disease relapses.

Espinosa G, Rodríguez-Pintó I, Gomez-Puerta JA, Pons-Estel G, Cervera R; Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum on Antiphospholipid Antibodies).

Semin Arthritis Rheum. 2013 Feb;42(4):417-23. doi: 10.1016/j.semarthrit.2012.05.005. Epub 2012 Jul 10.

PMID:
22784445
39.

Anti-citrullinated peptide antibodies in the serum of heavy smokers without rheumatoid arthritis. A differential effect of chronic obstructive pulmonary disease?

Ruiz-Esquide V, Gómara MJ, Peinado VI, Gómez Puerta JA, Barberá JA, Cañete Jde D, Haro I, Sanmartí R.

Clin Rheumatol. 2012 Jul;31(7):1047-50. doi: 10.1007/s10067-012-1971-y. Epub 2012 Mar 31.

PMID:
22466712
40.

B-cell depleting agents for ANCA vasculitides: a new therapeutic approach.

Gómez-Puerta JA, Quintana LF, Stone JH, Ramos-Casals M, Bosch X.

Autoimmun Rev. 2012 Jul;11(9):646-52. doi: 10.1016/j.autrev.2011.11.007. Epub 2011 Nov 21. Review.

PMID:
22146313
41.

Effects of smoking on disease activity and radiographic progression in early rheumatoid arthritis.

Ruiz-Esquide V, Gómez-Puerta JA, Cañete JD, Graell E, Vazquez I, Ercilla MG, Viñas O, Gómez-Centeno A, Haro I, Sanmartí R.

J Rheumatol. 2011 Dec;38(12):2536-9. doi: 10.3899/jrheum.110410. Epub 2011 Nov 1.

PMID:
22045838
42.

The use of chimeric vimentin citrullinated peptides for the diagnosis of rheumatoid arthritis.

Malakoutikhah M, Gómara MJ, Gómez-Puerta JA, Sanmartí R, Haro I.

J Med Chem. 2011 Nov 10;54(21):7486-92. doi: 10.1021/jm200563u. Epub 2011 Oct 7.

PMID:
21981664
43.

[Biomarkers in rheumatoid arthritis].

Sanmartí R, Gómez-Puerta JA.

Reumatol Clin. 2011 Mar;6S3:S25-8. doi: 10.1016/j.reuma.2010.10.007. Epub 2011 Mar 5. Review. Spanish.

44.

Relapsing polychondritis: a new adverse event secondary to the use of tumour necrosis factor antagonists?

Hernández MV, Ruiz-Esquide V, Gómez-Caballero ME, Gómez-Puerta JA, Cañete JD, Sanmartí R.

Rheumatology (Oxford). 2011 Aug;50(8):1523-5. doi: 10.1093/rheumatology/ker144. Epub 2011 May 18. No abstract available.

PMID:
21593064
45.

Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: report of 31 cases and review of the literature.

Pons-Estel GJ, Salerni GE, Serrano RM, Gomez-Puerta JA, Plasin MA, Aldasoro E, Lozano M, Cid J, Cervera R, Espinosa G.

Autoimmun Rev. 2011 Sep;10(11):679-84. doi: 10.1016/j.autrev.2011.04.028. Epub 2011 May 1. Review.

PMID:
21569864
46.

Therapy: Spleen tyrosine kinase inhibitors--novel therapies for RA?

Gómez-Puerta JA, Bosch X.

Nat Rev Rheumatol. 2011 Mar;7(3):134-6. doi: 10.1038/nrrheum.2011.8. Epub 2011 Feb 8.

PMID:
21304505
47.

Antibodies against β-fibrin synthetic peptides: a study of their association with the immunogenetic background and disease course of rheumatoid arthritis patients.

Haro I, Gómara MJ, Pérez ML, Viñas O, Ercilla G, Gómez-Puerta JA, Sanmartí R.

Eur J Med Chem. 2011 Apr;46(4):1095-102. doi: 10.1016/j.ejmech.2011.01.024. Epub 2011 Jan 21.

PMID:
21295379
48.

Therapeutic targeting of B cells for rheumatic autoimmune diseases.

Engel P, Gómez-Puerta JA, Ramos-Casals M, Lozano F, Bosch X.

Pharmacol Rev. 2011 Mar;63(1):127-56. doi: 10.1124/pr.109.002006. Epub 2011 Jan 18. Review.

PMID:
21245206
49.

Lung sarcoidosis induced by TNF antagonists in rheumatoid arthritis: a case presentation and a literature review.

Gifre L, Ruiz-Esquide V, Xaubet A, Gómez-Puerta JA, Hernández MV, Sanmartí R.

Arch Bronconeumol. 2011 Apr;47(4):208-12. doi: 10.1016/j.arbres.2010.05.011. Epub 2010 Jul 17.

50.

[Young woman with relapsing arthritis].

Gómez-Puerta JA, García-Melchor E.

Reumatol Clin. 2010 Jan-Feb;6(1):58-62. doi: 10.1016/j.reuma.2009.03.003. Epub 2009 Nov 7. Spanish.

Supplemental Content

Loading ...
Support Center